Cargando…
The Role of Hepatitis C Virus Core Antigen Testing in the Era of Direct Acting Antiviral Therapies: What We Can Learn from the Protease Inhibitors
Direct-acting antiviral (DAA) therapies have revolutionised the treatment of hepatitis C virus (HCV). The financial cost of DAAs however is significant, and first generation protease inhibitors (PIs) also require frequent monitoring of viral RNA levels to guide treatment. In this context, we examine...
Autores principales: | Nguyen, Linh Thuy, Gray, Emma, O'Leary, Aisling, Carr, Michael, De Gascun, Cillian F. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5053597/ https://www.ncbi.nlm.nih.gov/pubmed/27711230 http://dx.doi.org/10.1371/journal.pone.0163900 |
Ejemplares similares
-
Hepatitis C Virus Core Mutations Associated with False-Negative Serological Results for Genotype 3a Core Antigen
por: Nguyen, Linh Thuy, et al.
Publicado: (2015) -
Effectiveness of triple therapy with direct-acting antivirals for hepatitis C genotype 1 infection: application of propensity score matching in a national HCV treatment registry
por: Gray, Emma, et al.
Publicado: (2017) -
Hepatitis C in the era of direct-acting antivirals: real-world costs of untreated chronic hepatitis C; a cross-sectional study
por: Kieran, Jennifer Ann, et al.
Publicado: (2015) -
Human Polyomavirus Reactivation: Disease Pathogenesis and Treatment Approaches
por: De Gascun, Cillian F., et al.
Publicado: (2013) -
Management of hepatitis C genotype 4 in the directly acting antivirals era
por: Hathorn, Emma, et al.
Publicado: (2016)